Vasculitis
MONDO:0018882Vasculitis represents a clinically heterogenous group of diseases of multifactorial etiology characterized by inflammation of either large-sized vessels (large-vessel vasculitis, e.g. Giant-cell arteritis and Takayasu arteritis), medium-sized vessels (medium-vessel vasculitis e.g. polyarteritis nodosa and Kawasaki disease), or small-sized vessels (small-vessel vasculitis, e.g. granulomatosis with polyangiitis, microscopic polyangiitis, immunoglobulin A vasculitis, and cutaneous leukocytoclastic angiitis). Vasculitis occurs at any age, may be acute or chronic, and manifests with general symptoms such as fever, weight loss and fatigue, as well as more specific clinical signs depending on the type of vessels and organs affected. The degree of severity is variable, ranging from life or sight threatening disease (e.g. Behcet disease) to relatively minor skin disease.
Also known as: systemic vasculitis, angiitis
286 clinical trials for this condition and its sub-types, 63 tagged with Vasculitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vasculitis
-
Necrotizing vasculitis 0 trials · 143 incl. sub-types
3 sub-types
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 82 trials · 130 incl. sub-types Sub-types →
- Immunoglobulin A vasculitis 16 trials
- Disseminated visceral giant cell angiitis 0 trials
-
Arteritis 5 trials · 104 incl. sub-types
7 sub-types
- Granulomatous angiitis 0 trials · 52 incl. sub-types Sub-types →
- Microscopic polyangiitis 34 trials
- Takayasu arteritis 27 trials
- Polyarteritis nodosa 7 trials · 9 incl. sub-types Sub-types →
- Cerebral arteritis 0 trials
- Endarteritis 0 trials
- Juvenile temporal arteritis 0 trials
-
Central nervous system vasculitis 3 trials · 55 incl. sub-types
5 sub-types
- Temporal arteritis 52 trials Sub-types →
- Primary central nervous system vasculitis 2 trials Sub-types →
- Benign angiitis of the central nervous system 0 trials
- Central nervous system AIDS arteritis 0 trials
- Cerebral arteritis 0 trials
-
Phlebitis 13 trials · 21 incl. sub-types
1 sub-type
- Thrombophlebitis 6 trials · 9 incl. sub-types Sub-types →
-
Immune complex mediated vasculitis 0 trials · 18 incl. sub-types
5 sub-types
- Immunoglobulin A vasculitis 16 trials
- Cryoglobulinemic vasculitis 4 trials Sub-types →
- Hypocomplementemic urticarial vasculitis 2 trials
- Cutaneous leukocytoclastic angiitis 1 trial
- Erythema elevatum diutinum 0 trials
-
Hypersensitivity vasculitis 0 trials · 16 incl. sub-types
2 sub-types
- Immunoglobulin A vasculitis 16 trials
- Allergic cutaneous vasculitis 1 trial
-
Kawasaki disease 15 trials
-
Cutaneous vasculitis 4 trials · 5 incl. sub-types
1 sub-type
- Allergic cutaneous vasculitis 1 trial
-
Deficiency of adenosine deaminase 2 3 trials
-
Retinal vasculitis 2 trials
-
Aortitis 1 trial
-
Livedoid vasculopathy 1 trial
-
Choroiditis 0 trials · 1 incl. sub-types
4 sub-types
- Serpiginous choroiditis 1 trial
- Infectious posterior uveitis 0 trials
- Multifocal choroiditis 0 trials Sub-types →
- Paraneoplastic uveitis 0 trials
-
Secondary vasculitis 0 trials · 1 incl. sub-types
2 sub-types
- Drug-induced vasculitis 1 trial
- Postinfectious vasculitis 0 trials
-
Shwartzman phenomenon 0 trials
-
Autoimmune vasculitis 0 trials
1 sub-type
- Rheumatoid vasculitis 0 trials
-
Lymphangitis 0 trials
-
Vasculitis, lymphocytic, nodular 0 trials
Most studied deeper sub-types
-
Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term
Disease control CompletedThis study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by review…
Sponsor: European EGPA Study Group • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Steroid showdown: can a tiny daily dose keep a rare disease at bay?
Disease control CompletedThis study looked at 159 people with granulomatosis with polyangiitis (GPA), a rare disease that causes inflammation of blood vessels. Participants were randomly assigned to either stay on a low 5 mg daily dose of prednisone or slowly stop it over six months. The goal was to see …
Phase 3 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental IL-2 treatment shows promise for Hard-to-Treat HCV vasculitis
Disease control CompletedThis study tested a drug called interleukin-2 (IL-2) in 10 people with hepatitis C-related vasculitis that did not get better with usual treatments. The goal was to see if IL-2 could boost the body's immune regulation and control the disease. Participants received IL-2 injections…
Phase 1/2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug aims to tame giant cell arteritis with fewer steroids
Disease control CompletedThis phase 3 trial tested secukinumab, a biologic drug, in 354 people with giant cell arteritis (GCA), a condition causing inflamed arteries. Participants received either secukinumab or a placebo, along with a steroid taper. The goal was to see if secukinumab could help more peop…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug aims to tame blood vessel inflammation without steroids
Disease control CompletedThis study tested the drug secukinumab (Cosentyx) in 151 adults with newly diagnosed giant cell arteritis, a condition causing inflamed blood vessels. Participants were in remission and received either secukinumab or a placebo, along with a steroid taper. The goal was to see if s…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can flu shots protect autoimmune patients?
Disease control CompletedThis study looked at how well flu vaccines (seasonal and H1N1) work in 234 adults with autoimmune diseases like lupus or vasculitis, some of whom were on steroids or immunosuppressants. Researchers measured antibody levels three weeks after each shot to see if the vaccine provide…
Phase 4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New combo therapy aims to tame rare blood vessel disease
Disease control CompletedThis study tested whether adding azathioprine to standard corticosteroid treatment helps people with certain types of vasculitis (blood vessel inflammation) achieve remission and avoid relapses. 114 newly diagnosed patients without poor prognosis factors took part. The goal was t…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
Psoriasis drug OTEZLA tested in everyday use
Disease control CompletedThis completed study observed over 1,000 people with psoriasis who were prescribed OTEZLA (apremilast) for the first time. Researchers tracked side effects, symptom improvement, and quality of life over several years. The goal was to see how well the drug works in real-world sett…
Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 14:49 UTC
-
Two-Minute sweat test could spot hidden nerve damage
Diagnosis CompletedThis study tested a device called SUDOSCAN, which measures sweat function in just two minutes, to see if it can detect small fiber nerve damage in people with autoimmune diseases (like lupus or rheumatoid arthritis) or unexplained pain. Researchers enrolled 139 adults and compare…
Sponsor: Hôpital Européen Marseille • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
New digital PET/CT could spot hidden artery inflammation and prevent blindness
Diagnosis CompletedGiant cell arteritis (GCA) causes inflamed arteries and can lead to blindness if not treated quickly. This study tested a new digital PET/CT scan that can see tiny arteries in the head, which older scans missed. 92 patients with suspected GCA got both a PET/CT and an ultrasound. …
Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 13:06 UTC
-
Can a vaccine test expose hidden immune weakness?
Knowledge-focused CompletedThis trial tests whether rituximab, a drug used for ANCA-associated vasculitis, leaves patients with a weakened immune system. Researchers give pneumococcal vaccines to patients treated with rituximab, patients with the disease but not on rituximab, and healthy volunteers. They c…
Phase 2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Massive study reveals hidden dangers of common steroid treatments
Knowledge-focused CompletedThis completed study looked at over 107,000 patients in Germany to understand the long-term side effects of systemic steroids (corticosteroids) used for conditions like asthma, COPD, and arthritis. Researchers compared patients who took steroids with those who did not, tracking r…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Kawasaki Kids' hearts under the microscope 5 years later
Knowledge-focused CompletedThis study looked at the heart health of 61 children who had Kawasaki disease 5 years earlier and were treated with IVIG. Researchers compared them to healthy children using blood tests, blood pressure, artery stiffness, and heart imaging. The goal was to find early signs of hear…
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC